Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302743 · ClinicalTrials.gov registry record · NA
Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.
A NA study, sponsored by Mike O'Callaghan Military Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT01302743: Clinical Trial NA study, sponsored by Mike O'Callaghan Military Hospital.
NCT01302743 is a NA study that was terminated before completion, run by Mike O'Callaghan Military Hospital. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01302743, a NA study, was terminated before completion, sponsored by Mike O'Callaghan Military Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether Cinnamon bark or water-soluble cinnamon is an effective nutraceutical for the initial treatment of diabetes when compared to standard therapy of Metformin.
Primary Outcome
Subjects will have baseline blood levels to measure HbA1c. Subjects will then take either cinnamon bark powder, water-soluble cinnamon extract or metformin for 90 days then blood levels of HbA1c and lipid panel will be drawn again.
Interventions
- DRUG Group 1: Metformin
- DIETARY_SUPPLEMENT Group 2: Cinnamon Bark
- DIETARY_SUPPLEMENT Group 3: Cinnulin PF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-12 |
| Phase | NA |
Why NCT01302743 stopped before completion
NCT01302743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Group 1: Metformin is the first listed.
NCT01302743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01302743 about?
NCT01302743 is a clinical study titled "Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.". The purpose of this study is to assess whether Cinnamon bark or water-soluble cinnamon is an effective nutraceutical for the initial treatment of diabetes when compared to standard therapy of Metformin.
What is the current status of trial NCT01302743?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2010-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01302743?
The interventions under investigation include: Group 1: Metformin (DRUG), Group 2: Cinnamon Bark (DIETARY_SUPPLEMENT), Group 3: Cinnulin PF (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01302743?
This trial is sponsored by Mike O'Callaghan Military Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01302743's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia